Organized Cervical Cancer Screening Program in Barretos, Brazil: Experience in 18 Municipalities of Sao Paulo State
Carregando...
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARGER
Autores
POSSATI-RESENDE, Julio Cesar
VAZQUEZ, Fabiana de Lima
BIOT, Sinval Tadeu
MAUAD, Edmundo Carvalho
TALARICO, Thais
FREGNANI, Jose Humberto Tavares Guerreiro
Citação
ACTA CYTOLOGICA, v.62, n.1, p.19-27, 2018
Resumo
Objectives: The aim of this report is to demonstrate the Barretos Cancer Hospital initiative of organizational, laboratorial, and human resources training in the implementation of an organized cervical screening program in low-resource settings. Methods: We developed a computational program to report all epidemiological, clinical, and laboratorial findings, and to trace all necessary information to recruit women for regular screening or for referral for complementary exams after liquid-based Pap test analyses. Results: All Pap tests were collected in liquid medium and in 2014 more than 160,000 tests were analyzed and 2,900 colposcopy examinations were performed. From 2012 to 2015, the percentage of exams collected increased from 54.6% in 2012 to 62.4% in 2013, 68.4% in 2014, and 71% in 2015. Per 1,000 Pap tests, 0.4 cases of invasive cancer were diagnosed; for in situ carcinoma, 1.9 cases were identified. More importantly, between 2011 and 2015, 89.4% of all carcinomas were detected at clinical stage 0 or I (in situ carcinoma), and only 5% at stages III and IV. Conclusions: Since the organized system was implemented, 98% of women have attended their recall for colposcopy. So far, we have not reached the target of 70% of women for this proposal, as recommended by the international standards. (C) 2017 S. Karger AG, Basel
Palavras-chave
Cervical cancer screening, Cervical cytology, Cervix, Cytology, Cervical screening programs
Referências
- Alfaro KM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2360-7
- Costa RFA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138945
- Branca M, 2015, ACTA CYTOL, V59, P361, DOI 10.1159/000441515
- Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
- Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
- Fregnani JHTG, 2013, ACTA CYTOL, V57, P69, DOI 10.1159/000343046
- Hakama M, 1986, SCREENING CANC UTERI, P76
- Instituto Brasileiro de Geografia e Estatistica, 2014, CONT REG
- Instituto Nacional de Cancer, 2011, PROGR NAC CONTR CANC
- Instituto Nacional de Cancer, 2011, ATL MORT CANC
- Instituto Nacional de Cancer, 2012, MAN GEST QUAL LAB CI
- INCA, 2016, EST 2016 INC CANC BR
- INCA, 2016, COORD GER AC ESTR CO
- Hidalgo JLT, 2016, EUR J CANCER PREV, V25, P423, DOI 10.1097/CEJ.0000000000000201
- Lorenzi AT, 2013, GYNECOL ONCOL, V131, P131, DOI 10.1016/j.ygyno.2013.07.092
- Macinko J, 2003, HEALTH SERV RES, V38, P831, DOI 10.1111/1475-6773.00149
- Mauad EC, 2009, RURAL REMOTE HEALTH, V9
- Mauad EC, 2010, DIAGN CYTOPATHOL, V38, P727, DOI 10.1002/dc.21287
- Miller Anthony B., 2000, International Journal of Cancer, V86, P440, DOI 10.1002/(SICI)1097-0215(20000501)86:3<440::AID-IJC22>3.3.CO;2-1
- Possati-Resende JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134445
- Rossi PG, 2015, BRIT J CANCER, V112, P667, DOI 10.1038/bjc.2015.11
- Sankaranarayanan R, 1988, CANC SURVIVAL DEV CO, P15
- Stein MD, 2013, AM J CLIN PATHOL, V140, P567, DOI 10.1309/AJCPWL36JXMRESFH
- Organization WH, 2002, NAT CANC CONTR PROGR